Mark D. Pegram, MD

A panel of experts offer future perspectives in HR+ breast cancer.

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

Dr Pegram discusses the use of oral SERDs in HR-positive metastatic breast cancer and biomarker testing practices for patients with metastatic disease.

A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

A panel of experts discuss navigating 2L treatment strategies.

A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.

A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.

A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.

Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.

Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.

Mark Pegram, MD, discusses implications of and safety data from the primary analysis of the DESTINY-Breast06 trial in HR+/HER2– metastatic breast cancer.

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.

A review of when to use the Breast Cancer Index for patients with HR+ breast cancer when deciding on endocrine therapy duration.

Experts discuss biomarkers used to determine if a patient with HR+ breast cancer will benefit from extended endocrine therapy.

Lee Schwartzberg, MD, FACP, explains the IDEAL study and data on the benefits of extended adjuvant endocrine therapy in HR+ breast cancer.

Drs Schwartzberg and Pegram debate the value of having patients undergo more than 1 multigene assay to predict their risk of recurrence.

Mark Pegram, MD, details the role of biomarkers in predicting recurrences in patients with HR+ breast cancer.

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.